|
Part 1
Small
Cell Lung Cancer and Progress over 20 years
Effort: B Achievement: F
Nimira Alimohamed MD; Gwyn Bebb,
MA, BMBCh, PhD, FRCPC
|
To view the complete article click
here (pdf format)
Small cell lung cancer (SCLC) is characterized by a rapid doubling
time, early development of metastatic disease and sensitivity to
chemotherapy and radiation. Despite additions to treatment regimens
over the past 20 years, including prophylactic cranial radiation,
improvements in survival with this disease have been modest: the
vast majority of patients with SCLC will die within 2 years.
Sponsorship of distribution of the Lung Cancer UPDATE
Part 1 supplement to Oncology Exchange’s November 2011
issue is funded by Boehringer Ingelheim Canada Ltd./Ltee.
To view the complete article click
here (pdf format)
|
